AstraZeneca Announced Enhertu Approved In China As The First HER2-Directed Therapy For Patients With HER2-Low Metastatic Breast Cancer
Portfolio Pulse from Charles Gross
AstraZeneca and Daiichi Sankyo's Enhertu has been approved in China for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer. The approval by China's National Medical Products Administration is based on the results of the DESTINY-Breast04 Phase III trial.
July 12, 2023 | 10:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Enhertu has received approval in China, potentially expanding its market and increasing revenues.
The approval of Enhertu in China is a significant milestone for AstraZeneca as it expands the market for the drug. This could lead to increased sales and revenues, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100